A novel assay for determination of androgenic or anti-androgenic activity of a serum sample or a test compound
CA 2419977 A1 · Owner: Hormos Medical Corporation · Inventors: Raivio, Taneli; Janne, Olli A.; Palvimo, Jorma J.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention concerns a method for determining the androgenic activity of a sample, comprising the steps of a) contacting the sample with a cell comprising a luciferase reporter plasmid,a fusion protein comprising a ligand-binding domain of the androgen receptor and a Gal4 DNA-binding domain said fusion protein being able to bind to binding sites in said luciferase reporter plasmid, a fusion protein comprising an N-terminal region of the androgen receptor and a protein being able to bind to the luciferase gene promoter, and an androgen receptor-interacting protein 3 b) allowing the , sample to incubate with said cell c) lysing said cell, d) measuring the luciferase activity …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 13, 2001. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended June 13, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 13, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.